We are live on ! Find out more
BC

Birchview Capital Portfolio holdings

AUM $176M
1-Year Est. Return 95.04%
This Fund
S&P 500
This Quarter Est. Return
-0.07%
1 Year Est. Return
+95.04%
3 Year Est. Return
+233.14%
5 Year Est. Return
+280.2%
10 Year Est. Return
+1,023.63%
AUM
$147M
AUM Growth
-$4.71M
Cap. Flow
+$154K
Cap. Flow %
0.1%
Top 10 Hldgs %
83.52%
Holding
56
New
7
Increased
6
Reduced
13
Closed
3

Top Buys

Rank Stock Value
1
KPTI icon
Karyopharm Therapeutics
KPTI
+$824K
2
NKTR icon
Nektar Therapeutics
NKTR
+$730K
3
ARNA
Arena Pharmaceuticals Inc
ARNA
+$645K
4
IFRX icon
InflaRx
IFRX
+$553K
5
CMTA
Clementia Pharmaceuticals Inc.
CMTA
+$486K

Top Sells

Rank Stock Value
1
CELG
Celgene Corp
CELG
+$1.91M
2
XLRN
Acceleron Pharma
XLRN
+$474K
3
CORT icon
Corcept Therapeutics
CORT
+$444K
4
SHPG
Shire pic
SHPG
+$403K
5
SLDB icon
Solid Biosciences
SLDB
+$287K

Sector Composition

Rank Sector Weight
1 Healthcare 95.63%
2 Energy 3.26%
3 Consumer Staples 0.26%
4 Industrials 0.25%
5 Consumer Discretionary 0.03%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
XLRN
26
DELISTED
Acceleron Pharma
XLRN
$582K 0.4%
12,000
-13,000
-52% -$474K
BIIB icon
27
Biogen
BIIB
$29.6B
$580K 0.39%
2,000
– –
PXD
28
DELISTED
Pioneer Natural Resource Co.
PXD
$568K 0.39%
3,000
– –
DRNA
29
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
$551K 0.37%
45,000
– –
FOLD
30
DELISTED
Amicus Therapeutics
FOLD
$531K 0.36%
34,000
– –
IFRX icon
31
InflaRx
IFRX
$255M
$516K 0.35%
+16,000
New +$553K
NKTR icon
32
Nektar Therapeutics
NKTR
$2.34B
$464K 0.32%
+633
New +$730K
XNCR icon
33
Xencor
XNCR
$1.45B
$455K 0.31%
12,300
– –
HROW icon
34
Harrow
HROW
$1.56B
$396K 0.27%
+180,000
New +$402K
YTEN
35
DELISTED
Yield10 Bioscience, Inc. Common Stock
YTEN
$382K 0.26%
282
– –
MYGN icon
36
Myriad Genetics
MYGN
$538M
$374K 0.25%
10,000
– –
TSRO
37
DELISTED
TESARO, Inc.
TSRO
$365K 0.25%
8,200
– –
SITO
38
DELISTED
SITO MOBILE, LTD
SITO
$363K 0.25%
140,000
– –
ICPT
39
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
$361K 0.25%
4,300
– –
APTX
40
DELISTED
Aptinyx Inc. Common Stock
APTX
$242K 0.16%
+10,000
New +$214K
OMED
41
DELISTED
OncoMed Pharmaceuticals, Inc.
OMED
$228K 0.16%
98,689
– –
CLVS
42
DELISTED
Clovis Oncology, Inc.
CLVS
$227K 0.15%
5,000
– –
AVEO
43
DELISTED
AVEO Pharmaceuticals, Inc.
AVEO
$226K 0.15%
10,000
– –
SLDB icon
44
Solid Biosciences
SLDB
$786M
$214K 0.15%
400
-933
-70% -$287K
TGTX icon
45
TG Therapeutics
TGTX
$8.5B
$197K 0.13%
+15,000
New +$206K
BIOL
46
DELISTED
Biolase, Inc.
BIOL
$165K 0.11%
54
-49
-48% -$185K
GNCA
47
DELISTED
Genocea Biosciences, Inc.
GNCA
$162K 0.11%
23,625
– –
GNMX
48
DELISTED
Aevi Genomic Medicine Inc
GNMX
$142K 0.1%
128,000
– –
ECYT
49
DELISTED
Endocyte, Inc. Common Stock
ECYT
$138K 0.09%
+10,000
New +$119K
CELGZ
50
DELISTED
Celgene Corporation Contingent Value Rights
CELGZ
$98K 0.07%
241,877
– –
1
2
3

Similar funds

RWA
Resolute Wealth Advisor Findlay, Ohio $176M AUM
BAM
Boyar Asset Management New York $176M AUM 20.04% 1-Year Est. Return
TIM
Tevis Investment Management Plano, Texas $176M AUM 18.14% 1-Year Est. Return
LWM
Lifetime Wealth Management Rockwall, Texas $176M AUM
PFA
Providence Financial Advisors Overland Park, Kansas $175M AUM
DAM
Draper Asset Management Smithtown, New York $176M AUM 37.45% 1-Year Est. Return
AF
Align Financial Hermantown, Minnesota $176M AUM
OA
Oceanside Advisors Mount Pleasant, South Carolina $175M AUM 17.96% 1-Year Est. Return

Birchview Capital's Q2 2018 Portfolio in Review

As of Q2 2018, Birchview Capital held 56 positions worth $147M, down 3.1% from $152M the previous quarter. Its ten largest holdings account for 84% of the portfolio.

Birchview Capital's Q2 2018 filing shows 7 new, 6 increased, 13 reduced and 3 closed positions. Its largest new stake was Karyopharm Therapeutics: 3,333 shares worth $850K. The largest sale was Celgene Corp, an estimated $1.91M.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, down from 96% a quarter earlier, followed by Energy and Consumer Staples.

  • Birchview Capital's largest Q2 2018 buy was Karyopharm Therapeutics: 3,333 shares worth $850K.
  • Birchview Capital added most to Arena Pharmaceuticals Inc in Q2 2018, an estimated $645K increase.
  • Birchview Capital's biggest Q2 2018 reduction was Celgene Corp, cutting an estimated $1.91M.
  • Birchview Capital fully exited Shire pic in Q2 2018, selling an estimated $403K.
  • Birchview Capital's ten largest holdings make up 84% of its $147M portfolio in Q2 2018.
  • Birchview Capital opened 7 new positions and closed 3 in Q2 2018.
  • Birchview Capital's portfolio value fell 3.1% quarter-over-quarter to $147M.

Based on Birchview Capital's 13F filing for Q2 2018, filed 2 Aug 2018.